Daniel M Hartung1, Lindsey Alley2, Gillian Leichtling2, P Todd Korthuis3, Christi Hildebran2. 1. Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, United States; Oregon State University College of Pharmacy, 2730 SW Moody Ave., CL5CP, Portland, OR 97201, United States. Electronic address: hartungd@ohsu.edu. 2. HealthInsight Oregon, 2020 SW 4th Avenue, Suite 520, Portland, OR 97201, United States. 3. Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, United States.
Abstract
BACKGROUND: Oregon's Medicaid program is delivered through 16 Coordinated Care Organizations (CCOs) participating in a statewide performance improvement program to reduce high-dose opioid prescribing. CCOs were allowed flexibility to develop their own dose targets and any policies, trainings, guidelines, and/or materials to meet these targets. In this study, we characterize CCO strategies to reduce high-dose opioid prescribing across the 16 CCOs. METHODS: We reviewed relevant CCO documents and conducted semi-structured interviews with CCO administrators to acquire opioid-related policies, practices, timelines and contextual factors. We applied a systematic coding procedure to develop a comprehensive description of each CCO's strategy. We used administrative data from the state to summarize contextual utilization data for each CCO. RESULTS: Most CCOs selected a target daily morphine milligram equivalent (MME) dose of 90 mg. Sixteen issued quantity limits related to dose, eight restricted specific drug formulations (short-acting or long-acting), and 11 allowed for time-limited taper plan periods for patients over threshold. Many CCOs also employed provider trainings, feedback reports, and/or onsite technical assistance. Other innovations included incentive measures, electronic health record alerts, and toolkits with materials on local alternative therapy resources and strategies for patient communication. CCOs leveraging collaborations with regional partners appeared to mount a greater intensity of interventions than independently operating CCOs. CONCLUSIONS: CCOs developed a diversity of interventions to confront high-risk opioid prescribing within their organization. As healthcare systems mount interventions to reduce risky opioid prescribing, it is critical to carefully describe these activities and examine their impact on process and health outcomes.
BACKGROUND: Oregon's Medicaid program is delivered through 16 Coordinated Care Organizations (CCOs) participating in a statewide performance improvement program to reduce high-dose opioid prescribing. CCOs were allowed flexibility to develop their own dose targets and any policies, trainings, guidelines, and/or materials to meet these targets. In this study, we characterize CCO strategies to reduce high-dose opioid prescribing across the 16 CCOs. METHODS: We reviewed relevant CCO documents and conducted semi-structured interviews with CCO administrators to acquire opioid-related policies, practices, timelines and contextual factors. We applied a systematic coding procedure to develop a comprehensive description of each CCO's strategy. We used administrative data from the state to summarize contextual utilization data for each CCO. RESULTS: Most CCOs selected a target daily morphine milligram equivalent (MME) dose of 90 mg. Sixteen issued quantity limits related to dose, eight restricted specific drug formulations (short-acting or long-acting), and 11 allowed for time-limited taper plan periods for patients over threshold. Many CCOs also employed provider trainings, feedback reports, and/or onsite technical assistance. Other innovations included incentive measures, electronic health record alerts, and toolkits with materials on local alternative therapy resources and strategies for patient communication. CCOs leveraging collaborations with regional partners appeared to mount a greater intensity of interventions than independently operating CCOs. CONCLUSIONS: CCOs developed a diversity of interventions to confront high-risk opioid prescribing within their organization. As healthcare systems mount interventions to reduce risky opioid prescribing, it is critical to carefully describe these activities and examine their impact on process and health outcomes.
Authors: Catherine S Riggs; Sarah J Billups; Samantha Flores; Rachana J Patel; Rachel M F Heilmann; Jessica L Milchak Journal: J Manag Care Spec Pharm Date: 2017-03
Authors: Joseph W Frank; Travis I Lovejoy; William C Becker; Benjamin J Morasco; Christopher J Koenig; Lilian Hoffecker; Hannah R Dischinger; Steven K Dobscha; Erin E Krebs Journal: Ann Intern Med Date: 2017-07-11 Impact factor: 25.391
Authors: Daniel M Hartung; Jonah Geddes; Sara E Hallvik; P Todd Korthuis; Luke Middleton; Gillian Leichtling; Christi Hildebran; Hyunjee Kim Journal: BMC Health Serv Res Date: 2022-01-14 Impact factor: 2.655
Authors: Sanae El Ibrahimi; Sara Hallvik; Kirbee Johnston; Gillian Leichtling; Esther Choo; Daniel M Hartung Journal: Pharmacoepidemiol Drug Saf Date: 2020-08-10 Impact factor: 2.732
Authors: Alireza Boloori; Bengt B Arnetz; Frederi Viens; Taps Maiti; Judith E Arnetz Journal: Int J Environ Res Public Health Date: 2020-10-16 Impact factor: 3.390